DSIP Reconstitution and Storage Guide
What is DSIP, and why does that matter for reconstitution?
DSIP, chemically known as emideltide, is a synthetic nonapeptide originally studied for effects on sleep architecture. It is not a nutraceutical, not a dietary supplement in the legal sense, and not an FDA-approved drug. It has no approved indication, no approved dosage form, and no FDA-cleared route of administration. Because it lacks approval, there is no FDA label to consult for reconstitution volumes, diluent choice, storage temperature, or beyond-use dating. Anything circulating online about "how to mix DSIP" is derived from general peptide-handling convention, not from data specific to this molecule. That distinction matters more here than for most compounds, because the regulatory record for DSIP is unusually unfavorable (see DSIP FDA status 2026).
What is the current regulatory status, and does it affect sourcing?
DSIP's FDA Category 2 nomination for the 503A bulk drug substances list was withdrawn by the nominators themselves, according to the FDA's bulk drug substances page (content current as of 04/22/2026): https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks. Withdrawal of a nomination is not the same as approval, and it does not place DSIP on the 503A bulks list, which is the mechanism that would allow compounding pharmacies to prepare it legally under section 503A: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act. No enforcement discretion currently covers DSIP compounding.
On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee took up emideltide (DSIP) and voted against recommending it for the 503A bulks list: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026. This is not regulatory momentum toward eventual approval. It is the opposite: a formal committee rejection layered on top of a nomination that was already withdrawn. Anyone sourcing DSIP from a compounding pharmacy today is obtaining a product outside the pathway the FDA reserves for substances it has judged suitable for compounding. Track changes over time on the FDA Peptide Status Tracker.
Is there published stability data for reconstituted DSIP?
No study in the current biomedical literature addresses DSIP reconstitution, buffer compatibility, freeze-thaw tolerance, or post-mixing degradation. This is worth stating plainly rather than filling the gap with borrowed numbers from other peptides. Small peptide stability is not a generic property; degradation rate depends on the specific amino acid sequence, disulfide bonds (DSIP has none), oxidation-prone residues, and formulation pH, none of which have been characterized for DSIP in a controlled study that HealthRX.com has been able to verify. Claims that DSIP is stable for a specific number of days or weeks after reconstitution should be treated as unverified until a primary source is produced.
What do general small-peptide handling principles suggest, with the caveat that DSIP-specific data is absent?
Where peptide formulations do have approved handling instructions, such as bisoprolol oral liquid preparations designed for flexible dosing across pediatric and geriatric patients, the common threads are sterile diluent, controlled refrigeration, protection from light, and avoidance of repeated freeze-thaw cycles that can shear peptide bonds or promote aggregation (bisoprolol oral liquid formulation research). These are general pharmaceutical-formulation principles, not DSIP-specific findings, and the bisoprolol study does not evaluate DSIP or any neuropeptide. It is cited here only to illustrate that even approved liquid formulations require deliberate stability engineering, which underscores how much is unknown when that engineering has never been done for DSIP.
By extension, if someone is going to reconstitute a peptide product despite the absence of DSIP-specific data, standard laboratory-grade practice would involve using a sterile bacteriostatic or sterile water diluent (never tap or non-sterile water), reconstituting inside a clean and preferably still airflow environment, avoiding vigorous shaking that can denature the peptide, and refrigerating rather than freezing the mixed solution. None of this constitutes a validated protocol for DSIP. It is a description of general practice borrowed from other peptide handling, offered so the reader understands the baseline risks rather than as an endorsement.
What are the sterility and contamination risks specific to unsupervised reconstitution?
Reconstituting any injectable product outside a licensed pharmacy or clinical setting introduces contamination risk that has nothing to do with the peptide itself. Needles, vial stoppers, and diluent bottles that are reused or handled without sterile technique can introduce bacteria directly into a product intended for injection. Because DSIP is not FDA-approved, there is no manufacturer quality system, no batch testing requirement, and no adverse event reporting obligation attached to the products being sold. If a source cannot document third-party purity and sterility testing for the specific lot in hand, the product's contents and cleanliness are unverified.
When does storage error become a medical problem rather than a logistics one?
Signs that a reconstituted product may have degraded or become contaminated include visible cloudiness, particulate matter, discoloration, or an unusual odor. Any of these should be treated as a reason to discard the vial, not a cosmetic issue. If someone develops fever, chills, redness or swelling at an injection site, or signs of a systemic reaction after using a reconstituted peptide product of any kind, that is an urgent care situation, not something to monitor at home. Because DSIP has no established side effect profile from controlled trials, unexpected symptoms cannot be safely attributed to "known peptide effects." See DSIP side effects and safety for what has and has not been studied.
What is established, what is plausible, and what is not established
Established: DSIP has no FDA-approved indication or formulation. Its 503A nomination was withdrawn, and the FDA's compounding advisory committee separately voted against recommending it for that list in 2026. There is no FDA-sanctioned reconstitution or storage protocol for this molecule.
Plausible but unproven: general peptide-handling practices (sterile diluent, refrigeration, light protection, avoiding freeze-thaw) may reduce degradation risk for DSIP by analogy to other peptides, but this has not been confirmed by any DSIP-specific stability study identified in the current literature.
Not established: any specific shelf life, potency retention timeline, or safety margin for reconstituted DSIP. Any claim citing an exact number of days or weeks of post-reconstitution stability for DSIP should be treated as unverified until a primary source is produced.
DSIP Vial Verification and Handling Checklist
Before reconstituting any product sold as DSIP, work through this checklist rather than assuming standard peptide practice applies:
- Regulatory reality check - Confirm you understand DSIP has no FDA approval and is not on the 503A bulks list. If a seller implies otherwise, that is a red flag, not reassurance.
- Source documentation - Ask whether the seller can provide a certificate of analysis for the specific lot, including purity and sterility testing. No documentation means no verification of contents.
- Diluent choice - If proceeding despite the above, use only sterile bacteriostatic or sterile water intended for injection, never tap water or non-sterile saline substitutes.
- Technique - Reconstitute in a clean, low-traffic area, wipe vial stoppers with alcohol before each entry, and avoid reusing needles across vials.
- Storage discipline - Refrigerate (do not freeze) after mixing, keep away from light, and avoid repeated temperature cycling.
- Visual inspection before every use - Discard if cloudy, discolored, or containing particulates, regardless of how recently it was mixed.
- Symptom threshold - Treat fever, injection-site infection signs, or systemic reaction as an urgent care problem, not a wait-and-see issue.
This checklist reduces avoidable handling errors. It does not, and cannot, substitute for the FDA approval process, controlled manufacturing, or DSIP-specific stability data that do not currently exist.
The bottom line
The question that matters is not which diluent or refrigerator shelf is technically correct. It is whether reconstituting a substance with no approved formulation, no validated stability data, and a regulatory record that has moved toward rejection rather than approval is a decision that belongs outside a clinical setting at all. For background on the mechanism claims driving interest in DSIP, see DSIP mechanism, and for how it compares to substances with actual FDA-regulated pathways, see DSIP vs prescription sleep aids.